Ning Li, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
8
8
1
N/A
0
1
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Shoubin Wen, MD
Sound Biopharmaceuticals Ltd.
Shared therapeutic areas:
Worked with same sponsors:
Alice P Chen, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
James L Gulley, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jason Wu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Shared therapeutic areas:
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Worked with same sponsors:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
You Lu, MD
West China Hospital
Shared therapeutic areas:
E-mail: ClinicalTrials@ ImClone.com
Eli Lilly and Company
Shared therapeutic areas:
Rahul Aggarwal, MD
University of California, San Francisco
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites
Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy
Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Comparative Study of Different Neoadjuvant Therapies Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
GKL-006Allo Injection in Patients With Advanced Solid Tumors
All 8 trials loaded